GentiBio, a biotherapeutics company developing engineered regulatory T cells programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases, announced that it has closed a $20 million seed funding led by OrbiMed, Novartis Venture Fund and RA Capital Management, L.P. GentiBio also announced it has entered into exclusive licensing partnerships with Seattle Children’s Research Institute, Benaroya…